GlassScriptPhysician profile
Gretchen Folk
NPI 1144976085
$3,823.11
in general payments reported to CMS, 2019-2025
23 companies · $122 in 2025
The $122 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $843 · 2023: $1,461 · 2024: $1,397 · 2025: $122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,887 · Education: $92.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,887.27 |
| Education | $92.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $450.30 | 2022-2024 | Farxiga, Lokelma |
| Calliditas Therapeutics US INC. | $418.42 | 2022-2024 | Tarpeyo |
| Bayer Healthcare Pharmaceuticals INC. | $404.16 | 2022-2025 | |
| Aurinia Pharma U.S., INC. | $326.75 | 2022-2024 | Lupkynis |
| Amgen INC. | $240.38 | 2022-2025 | Tavneos, Krystexxa |
| Fresenius USA Marketing, INC. | $239.31 | 2022-2024 | Velphoro, Korsuva |
| Vifor Pharma, INC. | $199.08 | 2022-2024 | Veltassa |
| Novartis Pharmaceuticals Corporation | $195.05 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $170.83 | 2023-2024 | Jynarque |
| Mallinckrodt Hospital Products INC. | $148.83 | 2022-2024 | Acthar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $141.99 | 2023-2024 | Jardiance |
| Novo Nordisk INC | $127.32 | 2024 | Wegovy, Ozempic, Rybelsus |
| Alexion Pharmaceuticals, INC. | $110.03 | 2023-2024 | Ultomiris |
| Opko Pharmaceuticals, LLC | $106.70 | 2022-2023 | Rayaldee |
| Ardelyx, INC. | $89.88 | 2023-2024 | Ibsrela |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $87.37 | 2024 | Jardiance, Mounjaro |
| Daiichi Sankyo INC. | $80.37 | 2022-2024 | Injectafer |
| Glaxosmithkline, LLC. | $70.92 | 2022-2024 | Jesduvroq |
| Takeda Pharmaceuticals U.S.A., INC. | $67.43 | 2022-2023 | Gattex |
| Travere Therapeutics, INC. | $60.15 | 2022-2025 | Filspari |
| Ani Pharmaceuticals, INC. | $56.60 | 2022-2024 | Purified Cortrophin Gel |
| Ultragenyx Pharmaceutical INC. | $17.77 | 2023 | |
| Horizon Therapeutics Plc | $13.47 | 2023 | Krystexxa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gretchen Folk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.